Stephen L. Mayo's most recent trade in Allogene Therapeutics Inc was a trade of 144,400 Stock Option (Right to buy) done . Disclosure was reported to the exchange on June 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2026 | 144,400 | 144,400 | - | - | Stock Option (Right to buy) | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2026 | 16,875 | 18,640 (0%) | 0% | - | Common Stock | |
| Merck & Company | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2026 | 1,853 | 14,824 | - | - | Phantom Stock | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 12 Mar 2026 | 7,239 | 1,765 (0%) | 0% | 17.0 | 123,208 | Common Stock |
| Allogene Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 95,400 | 95,400 | - | - | Restricted Stock Unit | |
| Merck & Company | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 2,863 | 12,539 | - | - | Phantom Stock | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 4,792 | 4,792 | - | - | Stock Options (right to buy) | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 2,383 | 9,004 (0%) | 0% | - | Common Stock | |
| Allogene Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 191,082 | 191,082 | - | - | Stock Option (Right to buy) | |
| Merck & Company | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 1,752 | 9,379 | - | - | Phantom Stock | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Sale of securities on an exchange or to another person at price $ 122.96 per share. | 05 Mar 2024 | 3,135 | 6,621 (0%) | 0% | 123.0 | 385,480 | Common Stock |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,679 | 3,679 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 1,846 | 9,756 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Stephen L. Mayo | Director | Sale of securities on an exchange or to another person at price $ 4.29 per share. | 07 Aug 2023 | 10,000 | 25,328 (0%) | 0% | 4.3 | 42,855 | Common Stock |
| Allogene Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 116,120 | 116,120 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 1,980 | 7,430 | - | - | Phantom Stock | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 3,257 | 3,257 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 1,523 | 7,910 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Sale of securities on an exchange or to another person at price $ 109.92 per share. | 17 Nov 2022 | 858 | 6,387 (0%) | 0% | 109.9 | 94,311 | Common Stock |
| Allogene Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2022 | 54,487 | 54,487 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2022 | 35,328 | 35,328 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 2,363 | 5,297 | - | - | Phantom Stock | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 5,077 | 5,077 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 2,953 | 7,245 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 8,238 | 8,238 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Stephen L. Mayo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 4,292 | 4,292 (0%) | 0% | 0 | Common Stock |